Period of time: 2007年1-2期
Publisher: VSP
Founded in: 1991
Total resources: 26
ISSN: 1568-5608
Subject: R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Inflammopharmacology,volume 9,issue 1-2
Menu
Rheumatoid arthritis as seen through long-distance spectacles
By Buchanan W. W.,Kean Walter F. in (2001)
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.By Simpson Julie E.,Woodroofe M. Nicola in (2001)
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: A meta-analysis
By Ashraf E.,Cooper S.,Kellstein D.,Jayawardena S. in (2001)
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.Current issues on the safety of non-prescription NSAIDs
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.Caffeine as an analgesic adjuvant
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.Etodolac (Lodine ® ): Profile of an established selective COX-2 inhibitor
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.Review of gastrointestinal tolerability and safety of Meloxicam
By Degner Frank,Richardson Bill in (2001)
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.Clinical pharmacokinetics and metabolism of nimesulide
By Bernareggi Alberto in (2001)
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.The clinical developments and future of the COX-2 inhibitor drugs
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.Discovery and development of ML3000
Inflammopharmacology,volume 9,issue 1-2 , Vol. 9, Iss. 1-2, 2001-05 , pp.